L’Oréal Leads $30M Investment in AI Biotech PAM2L

Beauty giant L’Oréal is investing in the future of skincare, leading a $30 million Series A funding round for PAM2L Biotechnologies, a Shenzhen-based startup pioneering AI-native biomaterials. The investment was made through L’Oréal’s strategic corporate venture capital fund, BOLD, and co-led by Walgreens Boots Alliance, Guangzhou Pharmaceutical Group, and Guangxin Group.

Founded in 2021, PAM2L specialises in synthetic biology and recombinant proteins, including mussel adhesive proteins with applications in skincare and medicine. The company has raised more than 300 million RMB (approximately $45 million) in total funding to date.

The strategic partnership will bring together L’Oréal’s formulation expertise and PAM2L’s AI-driven biotechnology to develop and commercialise next-generation bio-based beauty ingredients. One ingredient, Augmented Colanic Acid, is already used in L’Oréal Paris Age Perfect Collagen Royal Series, demonstrating the commercial potential of PAM2L’s research.

“The investment in PAM2L marks a decisive new chapter in our commitment to harnessing China’s dynamic AI-enabled biotechnology ecosystem.”

Barbara Lavernos, L’Oréal Deputy CEO in charge of global Research, Innovation and Technology

PAM2L was also a winner of L’Oréal’s prestigious 2024 BIG BANG Beauty Tech Innovation Program, signalling the company’s long-term confidence in the startup’s science.

Source: Cosmetics Business — L’Oréal leads funding round for Chinese biotech company PAM2L

Move to the category:

Leave a Reply

Your email address will not be published. Required fields are marked *